classified as the company's shareholders (254 as of April 20XX, all closely held, not traded publicly). Instructions 1. Your team will analyze Chem-Med Company 2. Your team will play the role of a financial advisor, and will write a comprehensive report to your client whether or not to invest in Chem-Med Company. 3. Your report should have a well-defined introduction, body, and conclusion. 4. Use spreadsheet (Excel) to analyze the data; and weave the responses to question a) through g) into the main body of the report 5. The requirements for a) through g) can be found at the end of the case. 6. Your paper should follow APA style format (include citations and references). 7. Supplemental: A brief write up on the lessons you learned from doing this assignment. In mid-20XU Chem-Med commenced the manufacture and distribution of its first product, VISCAM, which is used to hold tissues in place during and after surgery of the retina. In March 20XV Chem-Med received regulatory approval to market another HA product known as VISCHY, which is used for the treatment of degenerative joint diseases in horses. The two products, VISCAM and VISCHY, are the only ones Chem-Med currently produces; however, the company has an active R&D (Research & Development) program investigating other applications. There are only two other manufacturers of FDA-approved HA products in the world: AB Fortia, a Swedish corporation, which manufactures a product called Healon in Sweden and distributes it in North America through a subsidiary, Pharmacia Inc., and Cilco Inc. in West Virginia. Chem-Med has about a 25 percent share of the market (for HA products in eye surgery) against Cilco's 16 percent and Pharmacia's 59 percent. Pharmacia, with the power of giant AB Fortia behind it, waged a continuing marketing war with Chem-Med, undercutting Chem-Med's prices and wooing its customers away at every opportunity. The matter came to a head in September 20XX, when Chem-Med filed a $13 million suit against Pharmacia, charging unfair trade practices. Dr. Swan was reasonably confident that Chem-Med would prevail in the suit, and in fact, Pharmacia had recently offered to settle out of court for $500,000. Chem-Med Company April 1, 20XX: Dr. Nathan Swan, age 40, chairman of the board of directors, chief executive officer, and founder of the Chem-Med Company, was in his office staring at the ceiling, wondering if he would not have been better off still teaching biochemistry at the University of Toronto. This business was getting to be a headache. Only a short time ago he was able to spend most of his time in the company lab comfortably working with test tubes and formulas. Lately, though, it seemed that all his waking hours were spent with financial statements and spreadsheets, and in meetings. He wanted the firm to grow and make money, but he had no idea that the financial end of the business would be so demanding and complex. Dr. Swan's primary problem was that although he was convinced the company was sound and would grow, he wasn't sure how to communicate that to potential investors in the financial community in a way that would convince them. Just handing out past income statements and balance sheets (shown in Tables 1 and 2) that he received from the accountants didn't seem to be enough. Further, he wasn't even sure the company needed outside financing, let alone how much. He just believed they would need it, since they had always had to ask for money in the past. CHEM-MED COMPANY Income Statements Dr. Swan was a little mystified by financial matters. How could one describe a company in financial terms? How could financial statements indicate whether or not a firm was in good or bad shape? (The balance in the company chequing account didn't seem to be an indicator.) How could one convince a group of hard-nosed investors that the company was capable of making a lot of money in the next few years, if it just had more money now? (Dr. Swan was always puzzled by the fact that Chem-Med was growing and making money, but it never seemed to have enough cash.) Chem-Med began operations 18 years ago after Dr. Francois Swan completed the development of commercial-scale isolation of sodium hyaluronate (hereafter referred to as HA), a naturally occurring biological fluid that is useful in eye surgery and other medical and veterinary uses. The isolation process, complex and proprietary to the company, involves extracting and purifying HA from rooster combs. Initial seed money for the enterprise came from research grants from the University of Toronto and the federal government, plus contributions from Dr. Swan's colleagues and associates, who were now 20XU-20xw (in thousands) Pro Forma Income Statements 20XV 20XW 20XX 20XY 20XZ 20XU $ 777 $3,051 Net sales (all credit) Cost of goods sold.. Gross profit. 257 995 $3,814 $5,340 $7,475 $10,366 1,040 1,716 2,154 2,954 2,774 3,624 5.321 7,412 520 2,056 Selling, etc., expenses 610 705 964 1,520 2,120 2,645 1,901 2,298 2,917 4.301 5,531 8,923 Other income (expenses)* 0 0 0 413 0 500 0 81 0 346 82 LUU 522 588 1,810 (90) 1,351 2,604 3,201 Operating profit. 1,820 8.335 3,888 2,216 4,767 2,571 5,009 Interest expense. 0 11 75 94 202 302 434 101 200 200 215 399 Income before tax (101) 1,276 2,402 2,899 4,333 $2,223 1,716 $3,190 $4,491 $6,343 S8,641 $11.995 Income taxes. Property, plant, & equipment.. Less: Accumulated amortization....... Property, plant, & equipment net......... Other capital assets. Total assets. Liabilities Accounts payable. Short-term debt Total current liabilities... Long-term debt Total liabilities. (40% in 20XV; 33% thereafter, 0 510 566 793 957 1,430 S210 $ 405 S. 551 $771 $1,080 S 1.512 35 S 2,903 39 42 59 82 135 0 0 245 444 593 830 1,162 1,647 17 19 21 27 50 17 S 2,903 2.347 262 Net income. (S 101) $ 766 $1,150 $1,609 $1,942 Dividends paid. 0 0 0 0 0 Increase in retained earnings $(101) $ 766 $1,150 $1,609 $1,942 Average number of shares** 2,326 2,326 2,347 2,347 2,347 Earnings per share. (S0.04) S0.33 S0.49 S0.69 S0.83 Other comprende Gradinary gain and Com. Ie 2014X5500,000 ir apced from Pharmacia Inc., in tout of the Law Sharer are ex publicly traand TABLE 1 463 614 857 1,212 1,664 $1.24 Equity Common stock... 2,062 2,062 2,062 3,424 2,062 5,366 (101) 8.269 2,062 2,062 665 1,815 2,727 3,877 $3,190 $4,491 Retained carnings Total equity Total liabilities and equity. TABLE 2 what 1,961 CHEM-MED COMPANY 5,486 7,428 10,331 ---- S6,343 $8,640 S11,995 $2,223 Balance Sheets (in thousands) Pro Forma Balance Sheets as of Dec. 31, years ended: 20XX 20XY 20XZ 20XU 20XV 20xw Dr. Swan had lunch with his banker recently, and the banker mentioned several restrictive covenants the company would have to meet if it came to the bank for financing. The three covenants were The current ratio must be maintained above 2.25 to 1. The debt-to-assets ratio must be less than 0.3 to 1. Dividends cannot be paid unless earnings are positive. Dr. Swan didn't think he would have any trouble with those, but he wasn't sure. He would have to analyze the numbers before the next board of directors meeting, but he now had to meet with a representative of a supermarket chain. Assets $ 124 S 103S 167 $ 205 S422 S 101 Cash and equivalent. Accounts receivable. Inventories. 100 409 564 907 1,495 2,351 798 151 302 960 1.102 1,443 Other current 28 59 29 41 57 11 As a financial advisor you are considering the addition of Chem-Med to your clients portfolio, you are interested in the company's record of profitability, prospects for the future, degree of risk, and how it compares with others in the industry (shown in Table 3). From that point of view, write a report to your client addressing the following questions: Total current assets. 403 873 1,720 2,255 3,417 3,261 Biotechnology Industry Statistics - Median Company in Biological Products 20XU 20XV 20XW 2.5 2.3 2.4 1.2 1.1 1.3 5.5 5.6 5.7 Current ratio.. Quick ratio.. Inventory turnover. Total asset turnover.. Return on sales. Retum on assets. Retum on equity. a. Conduct a general research on the internet) on the Biotechnology industry in Canada and summarize your key findings to capture market size and competitive dynamics of this industry b. What was Chem-Med's rate of sales growth in 20XW? What is it forecasted to be in 20XX, 20XY, and 20XZ? c. What is the company's rate of net income growth in 20XX, 20XY, and 20XZ? Is projected net income growing faster or slower than projected sales? After computing these values, take a hard look at the 20XX income statement data to see if you want to make any adjustments. d. How does Chem-Med's current ratio for 20XW compare to Pharmacia's? How does it compare to the industry average? Compute Chem-Med's current ratio for 20XZ. Is there any problem with it? e. What is Chem-Med's total debt-to-assets ratio in 20XW, 20XX, 20XY, and 20XZ? Is any trend evident in the four-year period? Does Chem-Med in 20XW have more or less debt than the average company in the industry? f. What is Chem-Med's average accounts receivable collection period for 20XW, 20XX, 20XY, and 20XZ? Is the period getting longer or shorter? What are the consequences? g. How does Chem-Med's ROE compare to Pharmacia's and the industry for 20XW? Using the DuPont method, compare the positions of Chem-Med and Pharmacia by computing ROE from its components. Using the results, compare the sources of ROE for each company 1.15 1.16 1.18 4.00% 4.00% 4.64% 5.00% 5.90% 4.60% 7.64% 8.44% 12.29% Total debt to assets. 0.40 0.45 0.52 Selected Statistics, Pharmacia Company 20XU 20XV 20XW 2.8 2.7 2.8 1.5 1.3 1.6 Current ratio.. Quick ratio. Inventory turnover. Total asset turnover. Retum on sales. 5.6 5.7 5.8 1.9 2 1.9 6.00% 6.50% 7.00% 11.40% 13.00% 13.30% 19.04% 27.66% 29.56% 0.40 0.53 0.55 Retum on assets.. Return on equity Total debt to assets. Price-carnings ratio Average share price. TABLE 3 13.7 14 15 S21.78 $24.92 $31.50 classified as the company's shareholders (254 as of April 20XX, all closely held, not traded publicly). Instructions 1. Your team will analyze Chem-Med Company 2. Your team will play the role of a financial advisor, and will write a comprehensive report to your client whether or not to invest in Chem-Med Company. 3. Your report should have a well-defined introduction, body, and conclusion. 4. Use spreadsheet (Excel) to analyze the data; and weave the responses to question a) through g) into the main body of the report 5. The requirements for a) through g) can be found at the end of the case. 6. Your paper should follow APA style format (include citations and references). 7. Supplemental: A brief write up on the lessons you learned from doing this assignment. In mid-20XU Chem-Med commenced the manufacture and distribution of its first product, VISCAM, which is used to hold tissues in place during and after surgery of the retina. In March 20XV Chem-Med received regulatory approval to market another HA product known as VISCHY, which is used for the treatment of degenerative joint diseases in horses. The two products, VISCAM and VISCHY, are the only ones Chem-Med currently produces; however, the company has an active R&D (Research & Development) program investigating other applications. There are only two other manufacturers of FDA-approved HA products in the world: AB Fortia, a Swedish corporation, which manufactures a product called Healon in Sweden and distributes it in North America through a subsidiary, Pharmacia Inc., and Cilco Inc. in West Virginia. Chem-Med has about a 25 percent share of the market (for HA products in eye surgery) against Cilco's 16 percent and Pharmacia's 59 percent. Pharmacia, with the power of giant AB Fortia behind it, waged a continuing marketing war with Chem-Med, undercutting Chem-Med's prices and wooing its customers away at every opportunity. The matter came to a head in September 20XX, when Chem-Med filed a $13 million suit against Pharmacia, charging unfair trade practices. Dr. Swan was reasonably confident that Chem-Med would prevail in the suit, and in fact, Pharmacia had recently offered to settle out of court for $500,000. Chem-Med Company April 1, 20XX: Dr. Nathan Swan, age 40, chairman of the board of directors, chief executive officer, and founder of the Chem-Med Company, was in his office staring at the ceiling, wondering if he would not have been better off still teaching biochemistry at the University of Toronto. This business was getting to be a headache. Only a short time ago he was able to spend most of his time in the company lab comfortably working with test tubes and formulas. Lately, though, it seemed that all his waking hours were spent with financial statements and spreadsheets, and in meetings. He wanted the firm to grow and make money, but he had no idea that the financial end of the business would be so demanding and complex. Dr. Swan's primary problem was that although he was convinced the company was sound and would grow, he wasn't sure how to communicate that to potential investors in the financial community in a way that would convince them. Just handing out past income statements and balance sheets (shown in Tables 1 and 2) that he received from the accountants didn't seem to be enough. Further, he wasn't even sure the company needed outside financing, let alone how much. He just believed they would need it, since they had always had to ask for money in the past. CHEM-MED COMPANY Income Statements Dr. Swan was a little mystified by financial matters. How could one describe a company in financial terms? How could financial statements indicate whether or not a firm was in good or bad shape? (The balance in the company chequing account didn't seem to be an indicator.) How could one convince a group of hard-nosed investors that the company was capable of making a lot of money in the next few years, if it just had more money now? (Dr. Swan was always puzzled by the fact that Chem-Med was growing and making money, but it never seemed to have enough cash.) Chem-Med began operations 18 years ago after Dr. Francois Swan completed the development of commercial-scale isolation of sodium hyaluronate (hereafter referred to as HA), a naturally occurring biological fluid that is useful in eye surgery and other medical and veterinary uses. The isolation process, complex and proprietary to the company, involves extracting and purifying HA from rooster combs. Initial seed money for the enterprise came from research grants from the University of Toronto and the federal government, plus contributions from Dr. Swan's colleagues and associates, who were now 20XU-20xw (in thousands) Pro Forma Income Statements 20XV 20XW 20XX 20XY 20XZ 20XU $ 777 $3,051 Net sales (all credit) Cost of goods sold.. Gross profit. 257 995 $3,814 $5,340 $7,475 $10,366 1,040 1,716 2,154 2,954 2,774 3,624 5.321 7,412 520 2,056 Selling, etc., expenses 610 705 964 1,520 2,120 2,645 1,901 2,298 2,917 4.301 5,531 8,923 Other income (expenses)* 0 0 0 413 0 500 0 81 0 346 82 LUU 522 588 1,810 (90) 1,351 2,604 3,201 Operating profit. 1,820 8.335 3,888 2,216 4,767 2,571 5,009 Interest expense. 0 11 75 94 202 302 434 101 200 200 215 399 Income before tax (101) 1,276 2,402 2,899 4,333 $2,223 1,716 $3,190 $4,491 $6,343 S8,641 $11.995 Income taxes. Property, plant, & equipment.. Less: Accumulated amortization....... Property, plant, & equipment net......... Other capital assets. Total assets. Liabilities Accounts payable. Short-term debt Total current liabilities... Long-term debt Total liabilities. (40% in 20XV; 33% thereafter, 0 510 566 793 957 1,430 S210 $ 405 S. 551 $771 $1,080 S 1.512 35 S 2,903 39 42 59 82 135 0 0 245 444 593 830 1,162 1,647 17 19 21 27 50 17 S 2,903 2.347 262 Net income. (S 101) $ 766 $1,150 $1,609 $1,942 Dividends paid. 0 0 0 0 0 Increase in retained earnings $(101) $ 766 $1,150 $1,609 $1,942 Average number of shares** 2,326 2,326 2,347 2,347 2,347 Earnings per share. (S0.04) S0.33 S0.49 S0.69 S0.83 Other comprende Gradinary gain and Com. Ie 2014X5500,000 ir apced from Pharmacia Inc., in tout of the Law Sharer are ex publicly traand TABLE 1 463 614 857 1,212 1,664 $1.24 Equity Common stock... 2,062 2,062 2,062 3,424 2,062 5,366 (101) 8.269 2,062 2,062 665 1,815 2,727 3,877 $3,190 $4,491 Retained carnings Total equity Total liabilities and equity. TABLE 2 what 1,961 CHEM-MED COMPANY 5,486 7,428 10,331 ---- S6,343 $8,640 S11,995 $2,223 Balance Sheets (in thousands) Pro Forma Balance Sheets as of Dec. 31, years ended: 20XX 20XY 20XZ 20XU 20XV 20xw Dr. Swan had lunch with his banker recently, and the banker mentioned several restrictive covenants the company would have to meet if it came to the bank for financing. The three covenants were The current ratio must be maintained above 2.25 to 1. The debt-to-assets ratio must be less than 0.3 to 1. Dividends cannot be paid unless earnings are positive. Dr. Swan didn't think he would have any trouble with those, but he wasn't sure. He would have to analyze the numbers before the next board of directors meeting, but he now had to meet with a representative of a supermarket chain. Assets $ 124 S 103S 167 $ 205 S422 S 101 Cash and equivalent. Accounts receivable. Inventories. 100 409 564 907 1,495 2,351 798 151 302 960 1.102 1,443 Other current 28 59 29 41 57 11 As a financial advisor you are considering the addition of Chem-Med to your clients portfolio, you are interested in the company's record of profitability, prospects for the future, degree of risk, and how it compares with others in the industry (shown in Table 3). From that point of view, write a report to your client addressing the following questions: Total current assets. 403 873 1,720 2,255 3,417 3,261 Biotechnology Industry Statistics - Median Company in Biological Products 20XU 20XV 20XW 2.5 2.3 2.4 1.2 1.1 1.3 5.5 5.6 5.7 Current ratio.. Quick ratio.. Inventory turnover. Total asset turnover.. Return on sales. Retum on assets. Retum on equity. a. Conduct a general research on the internet) on the Biotechnology industry in Canada and summarize your key findings to capture market size and competitive dynamics of this industry b. What was Chem-Med's rate of sales growth in 20XW? What is it forecasted to be in 20XX, 20XY, and 20XZ? c. What is the company's rate of net income growth in 20XX, 20XY, and 20XZ? Is projected net income growing faster or slower than projected sales? After computing these values, take a hard look at the 20XX income statement data to see if you want to make any adjustments. d. How does Chem-Med's current ratio for 20XW compare to Pharmacia's? How does it compare to the industry average? Compute Chem-Med's current ratio for 20XZ. Is there any problem with it? e. What is Chem-Med's total debt-to-assets ratio in 20XW, 20XX, 20XY, and 20XZ? Is any trend evident in the four-year period? Does Chem-Med in 20XW have more or less debt than the average company in the industry? f. What is Chem-Med's average accounts receivable collection period for 20XW, 20XX, 20XY, and 20XZ? Is the period getting longer or shorter? What are the consequences? g. How does Chem-Med's ROE compare to Pharmacia's and the industry for 20XW? Using the DuPont method, compare the positions of Chem-Med and Pharmacia by computing ROE from its components. Using the results, compare the sources of ROE for each company 1.15 1.16 1.18 4.00% 4.00% 4.64% 5.00% 5.90% 4.60% 7.64% 8.44% 12.29% Total debt to assets. 0.40 0.45 0.52 Selected Statistics, Pharmacia Company 20XU 20XV 20XW 2.8 2.7 2.8 1.5 1.3 1.6 Current ratio.. Quick ratio. Inventory turnover. Total asset turnover. Retum on sales. 5.6 5.7 5.8 1.9 2 1.9 6.00% 6.50% 7.00% 11.40% 13.00% 13.30% 19.04% 27.66% 29.56% 0.40 0.53 0.55 Retum on assets.. Return on equity Total debt to assets. Price-carnings ratio Average share price. TABLE 3 13.7 14 15 S21.78 $24.92 $31.50